These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1. Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114 [TBL] [Abstract][Full Text] [Related]
43. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma. Cheng M; Tao X; Wang F; Shen N; Xu Z; Hu Y; Huang P; Luo P; He Q; Zhang Y; Yan F Expert Opin Drug Metab Toxicol; 2024 Sep; 20(9):907-922. PubMed ID: 39225462 [TBL] [Abstract][Full Text] [Related]
44. EH-42: A Novel Small Molecule Induces Apoptosis and Inhibits Migration and Invasion of Human Hepatoma Cells through Suppressing STAT3 Signaling Pathway. Gong QZ; Xiao D; Gong GY; Xu J; Wen XD; Feng F; Qu W Curr Cancer Drug Targets; 2019; 19(7):583-593. PubMed ID: 30585547 [TBL] [Abstract][Full Text] [Related]
45. [Tumor-associated macrophages promote the proliferation and migration as well as invasion of sorafenib-resistant hepatocellular carcinoma cells]. Wei X; Pu J; Guo Z; Li T; Zhu D; Wu Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 May; 33(5):617-622. PubMed ID: 28502299 [TBL] [Abstract][Full Text] [Related]
46. Curcumin inhibits the proliferation and invasiveness of MHCC97-H cells via p38 signaling pathway. Zhang K; Rui X; Yan X Drug Dev Res; 2014 Nov; 75(7):463-8. PubMed ID: 25195681 [TBL] [Abstract][Full Text] [Related]
47. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines. Sasaki R; Kanda T; Fujisawa M; Matsumoto N; Masuzaki R; Ogawa M; Matsuoka S; Kuroda K; Moriyama M Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397371 [TBL] [Abstract][Full Text] [Related]
48. The effects of urotensin II on migration and invasion are mediated by NADPH oxidase-derived reactive oxygen species through the c-Jun N-terminal kinase pathway in human hepatoma cells. Li YY; Shi ZM; Yu XT; Feng P; Wang XJ Peptides; 2017 Feb; 88():106-114. PubMed ID: 27988353 [TBL] [Abstract][Full Text] [Related]
49. Inhibition of cancer cell growth by oleanolic acid in multidrug resistant liver carcinoma is mediated via suppression of cancer cell migration and invasion, mitochondrial apoptosis, G2/M cell cycle arrest and deactivation of JNK/p38 signalling pathway. Gao C; Li X; Yu S; Liang L J BUON; 2019; 24(5):1964-1969. PubMed ID: 31786862 [TBL] [Abstract][Full Text] [Related]
50. Baicalein inhibits the invasion and metastatic capabilities of hepatocellular carcinoma cells via down-regulation of the ERK pathway. Chen K; Zhang S; Ji Y; Li J; An P; Ren H; Liang R; Yang J; Li Z PLoS One; 2013; 8(9):e72927. PubMed ID: 24039823 [TBL] [Abstract][Full Text] [Related]
51. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era. Juengpanich S; Topatana W; Lu C; Staiculescu D; Li S; Cao J; Lin J; Hu J; Chen M; Chen J; Cai X Int J Cancer; 2020 Oct; 147(7):1778-1792. PubMed ID: 32162677 [TBL] [Abstract][Full Text] [Related]
52. Pentoxifylline induces apoptosis of HepG2 cells by reducing reactive oxygen species production and activating the MAPK signaling. Wang Y; Dong L; Li J; Luo M; Shang B Life Sci; 2017 Aug; 183():60-68. PubMed ID: 28583366 [TBL] [Abstract][Full Text] [Related]
53. 4-Terpineol exhibits potent in vitro and in vivo anticancer effects in Hep-G2 hepatocellular carcinoma cells by suppressing cell migration and inducing apoptosis and sub-G1 cell cycle arrest. Liu S; Zhao Y; Cui HF; Cao CY; Zhang YB J BUON; 2016; 21(5):1195-1202. PubMed ID: 27837623 [TBL] [Abstract][Full Text] [Related]
54. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849 [TBL] [Abstract][Full Text] [Related]
55. Regorafenib for the treatment of unresectable hepatocellular carcinoma. Rimassa L; Pressiani T; Personeni N; Santoro A Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808 [TBL] [Abstract][Full Text] [Related]
56. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054 [TBL] [Abstract][Full Text] [Related]
57. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction. Wang R; Liu Y; Mi X; Chen Q; Jiang P; Hou J; Lin Y; Li S; Ji B; Fang Y Arch Biochem Biophys; 2020 Aug; 689():108415. PubMed ID: 32562663 [TBL] [Abstract][Full Text] [Related]
58. Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. Weng MC; Li MH; Chung JG; Liu YC; Wu JY; Hsu FT; Wang HE Biomed Pharmacother; 2019 Aug; 116():109032. PubMed ID: 31163381 [TBL] [Abstract][Full Text] [Related]
59. Effect of halofuginone on the inhibition of proliferation and invasion of hepatocellular carcinoma HepG2 cell line. Huo S; Yu H; Li C; Zhang J; Liu T Int J Clin Exp Pathol; 2015; 8(12):15863-70. PubMed ID: 26884857 [TBL] [Abstract][Full Text] [Related]
60. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]